Noteworthy Friday Option Activity: DDOG, LMND, VKTX

Lemonade (LMND) saw 13,270 options contracts trade today (≈1.3M underlying shares), equal to about 57% of its one‑month ADTV, led by 794 contracts in the $70 put expiring Jan 9, 2026 (≈79,400 shares). Viking Therapeutics (VKTX) recorded 13,740 contracts (≈1.4M shares), ~56.3% of its one‑month ADTV, driven by 4,126 contracts in the $60 call expiring Jan 16, 2026 (≈412,600 shares). The size and concentration of these option flows represent notable speculative positioning that could influence near‑term price action in the underlying equities.

Analysis

Market structure: The concentrated option flow (LMND ≈1.3M underlying shares = 57% ADV; VKTX ≈1.4M = 56% ADV) suggests two directional bets rather than broad repositioning. Winners: option buyers (directional speculators) and short-term liquidity providers; losers: passive holders if delta-hedging creates directional flow (LMND likely downward, VKTX upward). Market makers face gamma risk into the Jan 9/Jan 16, 2026 expiries and will hedge dynamically, amplifying spot moves as open interest concentrates at $70 (LMND puts) and $60 (VKTX calls).

Risk assessment: Tail risks include a negative LMND corporate/regulatory event (insurance reserve shock, reinsurance withdrawal) or a VKTX clinical/FDA failure that would wipe >50% of value for small biotech. Immediate (days): gamma-driven volatility; short-term (weeks–months): earnings/trial readouts and IV re-pricing; long-term (≥1 year): fundamental business outcomes. Hidden dependencies: borrow availability for shorts, IV skew shifts, and block-trade origin (institutional hedge vs. retail speculation) that change directional interpretation. Key catalysts: LMND earnings/releases and VKTX trial/FDA milestones between now and Jan 2026, plus IV moves >20% from current levels.

Trade implications: For LMND, consider a defined-risk bearish spread: buy Jan 9 2026 $70/$55 put spread sized 1–2% portfolio notional, stop if spread premium drops 30% or if LMND > $85 for 10 trading days. For VKTX, consider a Jan 16 2026 $40/$60 call debit spread (buy $40, sell $60) sized 1–2% notional; target 50–100% return or close if adverse move of 25% from entry. Pair trade: long VKTX call spread and short (or hedge) LMND equity to neutralize market beta; enter within 5 trading days while IV is stable.

Contrarian angles: High single-strike volume can be non-directional (block hedges or structured product positioning); current flow may be over-interpreted as pure sentiment. If LMND put flow is mostly writing, a squeeze could invert the expected move; likewise, large VKTX call selling could cap upside. Historical parallels: concentrated strike blocks before sharp mean-reversions in small caps. Maintain liquidity hedges (small long-dated straddle on each ticker sized 0.25–0.5% portfolio) to guard against gamma squeezes.

Key Decisions for Investors

• Establish a 1–2% portfolio notional bearish put spread on LMND: buy Jan 9 2026 $70 / sell $55 put spread. Use limit pricing, risk max = premium paid, exit partial at +50% and fully at +100% or if LMND > $85 for 10 trading days.
• Establish a 1–2% portfolio bullish call spread on VKTX: buy Jan 16 2026 $40 / sell $60 call spread to cap cost. Target 50–100% return; cut if position declines 25% intratrade or fundamental news is negative.
• Implement a relative-value pair: long the VKTX call spread and short 0.5–1% notional LMND equity (or buy LMND put spread) to reduce market beta; rebalance if net IV moves >20% versus 30-day average.
• If implied volatility for either ticker rises >20% vs. its 30-day mean, switch to credit spreads (sell verticals) to harvest premium; if IV rank >60% consider selling OTM credit spreads one month from expiry to monetize elevated skew.